| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Payment of deferred debt issuance costs | 178 | - |
| Net cash provided by financing activities | 12,203 | 15,574 |
| Net decrease in cash, cash equivalents and restricted cash | -15,691 | -1,967 |
| Cash and cash equivalents at beginning of period | 102,920 | - |
| Cash and cash equivalents at end of period | 87,229 | - |
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)